Clinical trials: Chemoradiotherapy
Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms
An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation
The purpose of this study is to determine whether [18F]-ML-10 used in conjunction with PET imaging is effective as an imaging tool for the early detection of response of oncological tumors in the lungs,head and neck to…
- Trial name
- NCT01260480
- Testing
- [18F]-ML-10 in conjunction with PET imaging
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Aposense Ltd.
Nasopharyngeal Carcinoma
Neoadjuvant Chemotherapy and Low-dose Radiotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma（NPC）is common malignant tumor in China. The incidence of NPC in most parts of the world and the country is less than 1/10 million, but the incidence rate in China's Guangdong, Guangxi, Fujian and other…
- Trial name
- NCT05292027
- Testing
- low-dose radiotherapy
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Cancer
Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma
OBJECTIVES: This study proposes to evaluate the feasibility of delivery of this treatment in terms of toxicity. If toxicity is not acceptable, the treatment is not feasible.
- Trial name
- NCT00983541
- Testing
- Fluorouracil (5-FU), Brachytherapy or SBRT (Stereotactic body radiation therapy), Gemcitabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Resectable Esophageal Squamous Cell Carcinoma
Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
Evaluating the efficacy and safety of PD-L1 (Programmed Death-L1)antibody combined with endoscopy and radiotherapy for inoperable cT1b-2 (clinical stage tumor 1b-2) esophageal squamous cell carcinoma
- Trial name
- NCT06599775
- Testing
- Adebrelimab injection, Albumin-Bound Paclitaxel, Carboplatin injection
- Volunteers
- 42 people
- Sponsor
- Shanghai Zhongshan Hospital
Glioblastoma (GBM)
Efficacy of Zoster Vaccination in Glioblastoma Patients
In modern practice a trimodality treatment has emerged as standard of care for histologically confirmed glioblastoma. We hypothesize that the additional vaccination against herpes zoster, after surgical resection followed by…
- Trial name
- STARGATE (NCT07546669)
- Testing
- Additional vaccination against shingles (herpes zoster), Standard of care treatment without additional vaccination
- Volunteers
- 230 people
- Sponsor
- University Hospital, Essen
Squamous Cell Carcinoma of the Head and Neck
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
This study is being done to test whether panitumumab, in combination with chemotherapy and radiation is safe in people with head and neck cancer.
- Trial name
- NCT00513383
- Testing
- Panitumumab, Carboplatin, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
This Phase 2a/2 study evaluates the safety, tolerability, and efficacy of neoadjuvant and adjuvant NAI, hAd5-HPV vaccine (IBRX-042), and nab-paclitaxel in participants with locally advanced HPV-positive oropharyngeal squamous…
- Conditions
- HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT07628062
- Testing
- Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-042), Nab-Paclitaxel
- Volunteers
- 70 people
- Sponsor
- ImmunityBio, Inc.
Locally Advanced Head and Neck Cancer
Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer
Background: Locally advanced head and neck cancer (HNC) is a challenge as, in spite of initial good control with chemoradiation, the majority of patients fails systemically.
- Trial name
- NCT03532737
- Testing
- Pembrolizumab
- Where
- Kuwait
- Volunteers
- 50 people
- Sponsor
- Kuwait Cancer Control Center
Nasopharyngeal Neoplasms
Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
This trial intends to enroll patients with T4N1 or T1-4N2-3 (AJCC 8th) locoregionally-advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- NCT04870905
- Testing
- Tis-U-Sol
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Locally Advanced Cervical Cancer
Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer
Cadonilimab（AK104）is a humanized IgG1 bispecific antibody that targets PD-1 and CTLA-4. This is a single-arm, multicenter, open-label, phase II study, the purpose of this study is to evaluate the efficacy and safety of…
- Trial name
- NCT05687851
- Testing
- Cadonilimab（AK104）, EBRT, BT
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Chongqing University Cancer Hospital
Gastric Cancer, Stomach Cancer
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation
Stomach cancer is the fifth most common digestive cancer and third main cause of death from cancer in the world. Modern management of Gastric cancer involves a multi-disciplinary approach involving surgical oncologists, medical…
- Trial name
- NCT04308837
- Testing
- Paclitaxel, Carboplatin, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer
Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer
This is an open label, multi-institutional, single arm Phase II trial. All patients will be treated with Carboplatin, Paclitaxel, Durvalumab and Radiation.
- Trial name
- NCT03871153
- Testing
- Durvalumab, Paclitaxel, Carboplatin
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Greg Durm, MD
Non-Small Cell Lung Cancer, Radiation Induced Lung Injury (RILI)
Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation
Currently, the standard of care treatment for newly diagnosed, inoperable stage III non-small cell lung cancer is radiotherapy (RT) with concurrent chemotherapy, followed by immune checkpoint inhibitors (ICI).
- Trial name
- P4-PACIFIC (NCT06634056)
- Testing
- Pentoxifylline, α-Tocopherol
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- University Health Network, Toronto
Esophageal Cancer
Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma
This is a randomized noninferiority multicenter trial. Patients will be stratified according to the participating hospital. Patients will be randomized to one of the treatment arms.
- Trial name
- ASSURE (NCT03306901)
- Testing
- Esophagectomy, 5-fluorouracil, Cisplatin
- Where
- 9 sites in South Korea
- Volunteers
- 240 people
- Sponsor
- Samsung Medical Center
LOCALLY ADVANCED CERVICAL CANCERS
Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
This study is a clinical study to evaluate the safety and efficacy of Iparomlimab/Tuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies) in Combination With Concurrent…
- Trial name
- NCT07232654
- Testing
- Iparomlimab/Tuvonralimab, Cisplatin, Brachytherapy and External Beam Radiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer of Rectum
Evaluation of cfDNA as a Marker of Response in Rectal Cancer
A pathological complete response (pCR) after surgery occurs in approximately 20% of rectal cancer patients submitted to neoadjuvant chemotherapy, with apparent survival benefit.
- Trial name
- NCT04319354
- Testing
- Analysis of cfDNA
- Where
- Portugal
- Volunteers
- 50 people
- Sponsor
- Hospital Pedro Hispano
Esophageal Cancer
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
To learn if 18F-FAraG PET scans can find tumors in participants with esophageal cancer and predict a participant's response to treatment.
- Trial name
- NCT06414902
- Testing
- ArabinoFuranosylGuanine [18F]F-AraG
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer
This pilot clinical trial studies combination chemotherapy and radiation therapy before surgery followed by gemcitabine hydrochloride in treating patients with pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer
- Trial name
- NCT01821612
- Testing
- oxaliplatin, irinotecan, leucovorin
- Where
- 14 sites in United States
- Volunteers
- 23 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cervical Cancer
Cisplatin Based Chemoradiation v.s Radiotherapy for Cervical Cancer and With Clinically Defined Good Prognosis
This phase III study is designed to examine if low-risk, as defined by clinical and radiological parameters, stage IB-IIB cervical cancer patients treated by cisplatin-based chemoradiation, which is a recommended method by…
- Trial name
- NCT00846508
- Testing
- Cisplatin
- Where
- 2 sites in Taiwan
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Small Cell Lung Cancer Limited Stage
Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy
The phase II, randomised study is to explore the efficacy and safety of toripalimab as consolidation therapy in patients with limited-stage small cell lung cancer who have not progressed following concurrent chemoradiation therapy
- Trial name
- NCT04418648
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.